Trogenix Funding: $111M Raised, Series A (2025)

Trogenix funding overview

Trogenix is based in Edinburgh, United Kingdom. Trogenix has raised $111M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2025. The round record for Trogenix runs through 2025; nothing later has been disclosed. Investors on record include 4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital. 6 distinct backers are named across the disclosed rounds.

Trogenix at a glance

Total raised: $111M
Latest round: Series A
Latest round date: January 2025
Headquarters: Edinburgh, United Kingdom
Notable investors: 4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital

Frequently asked about Trogenix funding

How much has Trogenix raised?: Trogenix has raised $111M in total disclosed funding across the rounds on record.
Who has invested in Trogenix?: 4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital are named among the investors backing Trogenix.
What was the latest Trogenix funding round?: The most recent disclosed round is a Series A, announced in January 2025.
Where is Trogenix based?: Trogenix is based in Edinburgh, United Kingdom.
When did Trogenix last raise?: The last disclosed Trogenix round closed in January 2025 at Series A.

Totals shown for Trogenix aggregate every disclosed round on file. To see how that compares, browse the companies in Edinburgh and the investors behind them below.

Trogenix Funding: $111M Raised, Series A (2025)

Trogenix funding overview

Trogenix at a glance

Frequently asked about Trogenix funding

Companies related to Trogenix (23)

Browse related funding lists (5)